Literature DB >> 12067713

PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways.

Jifeng Zhang1, Mingui Fu, David Myles, Xiaojun Zhu, Jie Du, Xu Cao, Yuqing E Chen.   

Abstract

Osteoprotegerin (OPG) is a key regulator of osteoclastogenesis. Recent reports suggest that OPG may function as a protector of arterial calcification and survival of endothelial cells. However, the role and expression of OPG in vascular wall is unclear. Here we report that OPG was highly expressed in vascular smooth muscle cells (VSMC) but not in endothelial cells. Platelet-derived growth factor (PDGF), basic fibroblast growth factor, angiotensin II, tumor necrosis factor alpha and interleukin-1beta upregulated OPG expression in VSMC. Moreover, inhibition of phosphatidylinositol 3-kinase/Akt or P38-signal pathway abrogated PDGF-induced OPG expression. Our results suggest that OPG may be an important determinant of vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067713     DOI: 10.1016/s0014-5793(02)02872-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  31 in total

Review 1.  Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation.

Authors:  Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink
Journal:  Nat Rev Cardiol       Date:  2009-06-23       Impact factor: 32.419

2.  Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.

Authors:  Jingchao Lu; Fan Liu; Demin Liu; Hong Du; Jie Hao; Xiuchun Yang; Wei Cui
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-22

Review 3.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

4.  An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Authors:  Paola Secchiero; Federica Corallini; Assunta Pandolfi; Agostino Consoli; Riccardo Candido; Bruno Fabris; Claudio Celeghini; Silvano Capitani; Giorgio Zauli
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

5.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

6.  Glucose lowers the threshold for human aortic vascular smooth muscle cell migration: inhibition by protein phosphatase-2A.

Authors:  M Campbell; P Anderson; E R Trimble
Journal:  Diabetologia       Date:  2008-03-14       Impact factor: 10.122

7.  Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.

Authors:  Federico Biscetti; Giuseppe Straface; Silvia Giovannini; Angelo Santoliquido; Flavia Angelini; Luca Santoro; Carlo Filippo Porreca; Giovanni Pecorini; Giovanni Ghirlanda; Andrea Flex
Journal:  Hum Genet       Date:  2012-09-11       Impact factor: 4.132

8.  Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients.

Authors:  X Guang-Da; S Hui-Ling; C Zhi-Song; Z Lin-Shuang
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

9.  The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.

Authors:  L B Pritzker; M Scatena; C M Giachelli
Journal:  Mol Biol Cell       Date:  2004-04-02       Impact factor: 4.138

10.  RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain.

Authors:  Colin Davenport; Emma Harper; Keith D Rochfort; Hannah Forde; Diarmuid Smith; Philip M Cummins
Journal:  J Vasc Res       Date:  2018-04-10       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.